|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 796.53 USD | -0.38% |
|
-3.90% | +36.80% |
| 08:58pm | Swiss Market Index Recovers Ahead of Interest Rate Decision | MT |
| 05:34pm | Eli Lilly's Breast Cancer Drug Cuts Disease Progression, Improves Survival in Late-stage Trial | MT |
| Capitalization | 72TCr 69TCr 64TCr 56TCr 1,01800Cr 61,04400Cr 1,13100Cr 7,90900Cr 2,92900Cr 25,10200Cr 2,70500Cr 2,64500Cr 1,09,78400Cr | P/E ratio 2024 * |
63x | P/E ratio 2025 * | 37.1x |
|---|---|---|---|---|---|
| Enterprise value | 74TCr 71TCr 66TCr 58TCr 1,04800Cr 62,83600Cr 1,16400Cr 8,14100Cr 3,01500Cr 25,83900Cr 2,78400Cr 2,72200Cr 1,13,00600Cr | EV / Sales 2024 * |
16.2x | EV / Sales 2025 * | 12.5x |
| Free-Float |
99.81% | Yield 2024 * |
0.65% | Yield 2025 * | 0.75% |
More valuation ratios
* Estimated data
More news
Last Transcript: Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -0.44% | ||
| 1 week | -3.90% | ||
| Current month | +0.26% | ||
| 1 month | -4.20% | ||
| 3 months | -13.40% | ||
| 6 months | -7.90% | ||
| Current year | +36.80% |
1 week
786.37
841.00
1 month
711.40846.46
Current year
579.05972.53
1 year
561.65972.53
3 years
231.87972.53
5 years
117.06972.53
10 years
64.18972.53
| Director | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/2017 |
Ruth Gimeno
PSD | President | - | - |
Lucas Montarce
DFI | Director of Finance/CFO | 47 | 09/09/2024 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jon Fyrwald
BRD | Director/Board Member | 64 | 01/01/2005 |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/04/2009 |
| Director/Board Member | 52 | 12/12/2011 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 20 M€ | +16.14% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.38% | -3.90% | +36.54% | +220.87% | 72TCr | ||
| +1.00% | +1.32% | +18.10% | +107.40% | 49TCr | ||
| -1.45% | -2.34% | -5.24% | -12.77% | 36TCr | ||
| -0.75% | -1.20% | +15.27% | +37.81% | 31TCr | ||
| -1.23% | -1.38% | -4.21% | +36.17% | 26TCr | ||
| +0.83% | +0.87% | +0.63% | -31.81% | 23TCr | ||
| +0.25% | +0.55% | +4.38% | +27.76% | 21TCr | ||
| -0.92% | -2.40% | +2.76% | +17.98% | 20TCr | ||
| -0.47% | -0.91% | +1.32% | +30.44% | 15TCr | ||
| -1.23% | +0.29% | -11.65% | -54.16% | 14TCr | ||
| Average | -0.45% | -1.53% | +5.79% | +37.97% | 30.66TCr | |
| Weighted average by Cap. | -0.36% | -1.53% | +12.08% | +73.87% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 4.56TCr 4.35TCr 4.04TCr 3.58TCr 6.45TCr 3,87000Cr 7.17TCr 50TCr 19TCr 1,59100Cr 17TCr 17TCr 6,95900Cr | 5.86TCr 5.59TCr 5.18TCr 4.6TCr 8.28TCr 4,96700Cr 9.2TCr 64TCr 24TCr 2,04200Cr 22TCr 22TCr 8,93200Cr |
| Net income | 1.13TCr 1.08TCr 1TCr 889.77Cr 1.6TCr 96TCr 1.78TCr 12TCr 4.61TCr 40TCr 4.26TCr 4.17TCr 1,73000Cr | 1.96TCr 1.87TCr 1.73TCr 1.54TCr 2.77TCr 1,65900Cr 3.07TCr 21TCr 7.96TCr 68TCr 7.35TCr 7.19TCr 2,98400Cr |
| Net Debt | 2.11TCr 2.02TCr 1.87TCr 1.66TCr 2.99TCr 1,79200Cr 3.32TCr 23TCr 8.6TCr 74TCr 7.94TCr 7.76TCr 3,22300Cr | 1.31TCr 1.25TCr 1.16TCr 1.03TCr 1.85TCr 1,11200Cr 2.06TCr 14TCr 5.33TCr 46TCr 4.92TCr 4.82TCr 1,99900Cr |
More financial data
* Estimated data
Employees
43,000
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/24/12 | 796.61 $ | -0.37% | 1,778,622 |
| 10/24/10 | 799.58 $ | -0.50% | 2,695,247 |
| 09/24/09 | 803.58 $ | -2.80% | 3,175,956 |
| 06/24/06 | 826.71 $ | +0.13% | 3,047,127 |
| 05/24/05 | 825.62 $ | -0.51% | 2,423,388 |
Delayed Quote Nyse, December 12, 2024 at 01:18 am IST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
799.58USD
Average target price
984.05USD
Spread / Average Target
+23.07%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition